다가오는 이벤트 Ironwood Pharmaceuticals
모든 이벤트
예정된 향후 이벤트가 없습니다.
요약 분석 Ironwood Pharmaceuticals
수익 및 순이익 Ironwood Pharmaceuticals
모든 매개변수
주식 뉴스 Ironwood Pharmaceuticals
모든 뉴스
12 6월 2023 в 23:30
12 6월 2023 в 23:30
22 5월 2023 в 15:45
22 5월 2023 в 15:45
22 5월 2023 в 14:55
22 5월 2023 в 14:50
22 5월 2023 в 14:15
22 5월 2023 в 14:00
11 4월 2023 в 15:56
11 4월 2023 в 15:51
1 12월 2021 в 15:45
1 12월 2021 в 15:40
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist, which is in pre-clinical development for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
주소:
100 Summer Street, Boston, MA, United States, 02110
회사 이름:
Ironwood Pharmaceuticals
Ironwood Pharmaceuticals
발행자 티커:
IRWD
ISIN:
US46333X1081
국가:
미국
교환:
NASDAQ
통화:
$
IPO 날짜:
2010-02-03
부문:
보건 의료
산업:
생명공학
대지:
https://www.ironwoodpharma.com
https://www.ironwoodpharma.com
